APhA provides new pharmacist leadership opportunities
WASHINGTON — The American Pharmacists Association on Thursday announced a new Leadership360 Institute that provides pharmacists with opportunities to reach full leadership potential while developing management skills necessary across pharmacy settings.
Institute participants can take part in any or all of the three Leadership tracks including: Lead360, Mentor360, and Manage360. Each track will offer programs to help pharmacists excel in their individual growth, purposeful development and interactions with others.
"APhA is excited to offer a program that can help so many pharmacists enhance their career through our new Leadership360 Institute," stated Thomas Menighan, EVP and CEO of APhA. "Pharmacists have the knowledge and skills to provide excellent patient care services. APhA's new program will help pharmacists develop their skills as leaders on their healthcare teams, in pharmacy, and in their communities."
The Lead360 track launches with the Leader Within program that empowers participants to explore their values, interests, strengths and needs as they take a purposeful approach to life and leadership. The inaugural track starts with live programs in October to kick off American Pharmacists Month and participants can extend the experience through a three-month Virtual Experience.
The Mentor360 track offers pharmacists the opportunity to connect with leaders in the profession in two meaningful, yet different environments: Professional Connections and Practice Collaboratives. Mentor360: Professional Connections is APhA's one-on-one mentor program for pharmacists that pairs individuals seeking to learn more about key pharmacy interest areas with others who have identified those same topics as areas of expertise.
Mentor 360: Practice Collaboratives is APhA's small group-based mentor program that will bring pharmacists together to fuel innovation and progress toward advancing pharmacy practice. Each Practice Collaborative will include a panel of experts who share their knowledge on a defined topic area with a small group of participants through webinars and an exclusive online forum. The Mentor360 programs will launch in early September and is available for APhA's pharmacist members only.
And the Manage360 track will include online management training sessions that provide pharmacists with the skills and tactics they need to effectively manage staff, their practice setting, and themselves. Manage360 will launch in early 2018.
Mylan launches 3 HIV generics in Canada
HERTFORDSHIRE, England, PITTSBURGH and TORONTO — Mylan has launched three generics for treating HIV in Canada. Among the three launches is the company’s generic of Gilead’s Truvada (emtricitabine/tenofovir disoproxil fumarate, 200 mg/300 mg), as well as generics of Atripla (efavirenz, emtricitabine and tenofovir disoproxil fumarate, 600 mg/200 mg/300 mg) and Viread (tenofovir disoproxil, 300 mg).
“Mylan has a strong and sustained commitment to expanding access to treatment for HIV/AIDS and other diseases around the world, and today marks another milestone in those efforts,” Mylan chief commercial officer Tony Mauro said. “More than 40% of people worldwide being treated for HIV/AIDS with an antiretroviral depend on a Mylan product every day, and we're proud to further expand access to such medicines in Canada.”
Mylan has invested $250 million in expanding its antiretroviral production capabilities, enabling it to produce 4 billion antiretroviral tablets and capsules each year, the company said.
Makers of first ALS drug in 22 years announce availability
JERSEY CITY, N.J. — The first drug for ALS approved in 22 years is now available. Mitsubishi Tanabe Pharma America this week announced the introduction of its Radicava (edaravone), an intravenous treatment for ALS that the Food and Drug Administration approved on May 5.
“After 13 years of clinical research and investment, we have reached a seminal moment, which may shift the treatment paradigm for this terrible disease," Mitsubishi Tanabe Pharma America chief commercial officer Tom Larson said. “As of today, all across the country, conversations between ALS specialists and patients may be substantially different. We are all extremely proud and excited to be a part of bringing Radicava and new hope to patients in the U.S.”
In clinical trials, 33% of patients treated with Radicava showed a lower rate of decline in the loss of physical function, compared with those on a placebo. Currently, between 5,000 and 6,000 patients are diagnosed with ALS every year.
"This new treatment may give hope to every person suffering from ALS, and we pray the positive result from this trial will set the tone for more therapies going forward. We all remain committed," said Dr. Jonathan Katz, ALS Clinic Director of the Forbes Norris MDA/ALS Research and Treatment at California Pacific Medical Center.